Document ID: chunk:federal_register_of_legislation:F2025L00212:clause:1_5072
Version: federal_register_of_legislation:F2025L00212
Segment Type: clause
Provision Reference: sch 1 cl 5072
Character Range: 2361429–2362645

5072                                      UBIQUINOL-10                                   A, E      When used as an excipient, the route of administration must be topical and the concentration in the medicine must be no more than 0.05%.
                                                                                                   Not to be included in medicines intended for use in the eye.
                                                                                                   When for internal use, the maximum recommended daily dose must provide no more than 300 milligrams of ubiquinol-10.
                                                                                                   When used in combination with ubidecarenone, the maximum recommended daily dose must provide no more than 300 mg of ubiquinol-10 and ubidecarenone combined.
                                                                                                   The medicine requires the following warning statement on the medicine label:
                                                                                                   - (WARF) 'Do not take while on warfarin therapy without medical advice.'